羟乙基淀粉与生理盐水用于高危腹部大手术患者容量替代治疗对死亡或术后并发症的影响:FLASH随机临床试验
FLASH多中心双盲随机试验纳入775例术后肾损伤风险较高的腹部大手术成人患者,比较6%羟乙基淀粉130/0.4与0.9%生理盐水用于容量替代治疗。
要点
- 高危腹部大手术患者使用羟乙基淀粉与生理盐水相比,14天死亡或主要并发症复合终点无显著差异。
核心结论
- 在高危腹部大手术患者中,使用羟乙基淀粉进行容量替代治疗与0.9%生理盐水相比,14天内死亡或主要术后并发症复合终点无显著差异。
- 研究结果不支持在此类患者中使用羟乙基淀粉进行容量替代治疗。
研究设计与样本
- 多中心、双盲、平行组随机临床试验,在法国20所大学医院开展,2016年2月至2018年7月入组,末次随访2018年10月。
- 共纳入775例接受腹部大手术且术后肾损伤风险较高的成人患者,HES组389例,生理盐水组386例。
关键数值与推荐
- 主要终点为术后14天死亡或主要术后并发症的复合结局。
- 次要终点包括术后14天内预设并发症、ICU和住院时间、术后第28天和90天全因死亡率。
- 干预为6% HES 130/0.4溶于0.9%生理盐水或单用0.9%生理盐水,以250 mLbolus按个体化血流动力学算法于术中及术后第1天至次日7:59前给药。
临床怎么用
- 对于接受腹部大手术且术后肾损伤风险较高的患者,不应将羟乙基淀粉作为容量替代治疗的常规选择。
- 容量替代治疗可考虑使用0.9%生理盐水,并按个体化血流动力学算法调整。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: It is not known if use of colloid solutions containing hydroxyethyl starch (HES) to correct for intravascular deficits in high-risk surgical patients is either effective or safe. OBJECTIVE: To evaluate the effect of HES 130/0.4 compared with 0.9% saline for intravascular volume expansion on mortality and postoperative complications after major abdominal surgery. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, double-blind, parallel-group, randomized clinical trial of 775 adult patients at increased risk of postoperative kidney injury undergoing major abdominal surgery at 20 university hospitals in France from February 2016 to July 2018; final follow-up was in October 2018. INTERVENTIONS: Patients were randomized to receive fluid containing either 6% HES 130/0.4 diluted in 0.9% saline (n = 389) or 0.9% saline alone (n = 386) in 250-mL boluses using an individualized hemodynamic algorithm during surgery and for up to 24 hours on the first postoperative day, defined as ending at 7:59 am the following day. MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of death or major postoperative complications at 14 days after surgery. Secondary outcomes included predefined postoperative complications within 14 days after surgery, durations of intensive care unit and hospital stays, and all-cause mortality at postoperative days 28 and 90. RESULTS: Among 826 patients enrolled (mean age, 68 [SD, 7] years; 91 women [12%]), 775 (94%) completed the trial. The primary outcome occurred in 139 of 389 patients (36%) in the HES group and 125 of 386 patients (32%) in the saline group (difference, 3.3% [95% CI, -3.3% to 10.0%]; relative risk, 1.10 [95% CI, 0.91-1.34]; P = .33). Among 12 prespecified secondary outcomes reported, 11 showed no significant difference, but a statistically significant difference was found in median volume of study fluid administered on day 1: 1250 mL (interquartile range, 750-2000 mL) in the HES group and 1500 mL (interquartile range, 750-2150 mL) in the saline group (median difference, 250 mL [95% CI, 83-417 mL]; P = .006). At 28 days after surgery, 4.1% and 2.3% of patients had died in the HES and saline groups, respectively (difference, 1.8% [95% CI, -0.7% to 4.3%]; relative risk, 1.76 [95% CI, 0.79-3.94]; P = .17). CONCLUSIONS AND RELEVANCE: Among patients at risk of postoperative kidney injury undergoing major abdominal surgery, use of HES for volume replacement therapy compared with 0.9% saline resulted in no significant difference in a composite outcome of death or major postoperative complications within 14 days after surgery. These findings do not support the use of HES for volume replacement therapy in such patients. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02502773.
引用
- Futier E, Garot M, Godet T, et al. Effect of Hydroxyethyl Starch vs Saline for Volume Replacement Therapy on Death or Postoperative Complications Among High-Risk Patients Undergoing Major Abdominal Surgery: The FLASH Randomized Clinical Trial. JAMA. 2020. PMID: 31961418. doi:10.1001/jama.2019.20833
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。